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Background: Ovarian cancer has the highest mortality rate among all the gynecological cancers. 
This is mostly due to the resistance of ovarian cancer to current chemotherapy regimens. 
Therefore, it is of crucial importance to identify the molecular mechanisms associated with 
chemoresistance.
Methods: NCI/ADR-RES is a multidrug-resistant cell line that is a model for the study of drug resis-
tance in ovarian cancer. We carried out a microarray-derived transcriptional profiling analysis of 
NCI/ADR-RES to identify differentially expressed genes relative to its parental OVCAR-8.
Results: Gene-expression profiling has allowed the identification of genes and pathways that 
may be important for the development of drug resistance in ovarian cancer. The NCI/ADR-
RES cell line has differential expression of genes involved in drug extrusion, inactivation, and 
efficacy, as well as genes involved in the architectural and functional reorganization of the 
extracellular matrix. These genes are controlled through different signaling pathways, including 
MAPK–Akt, Wnt, and Notch.
Conclusion: Our findings highlight the importance of using orthogonal therapies that target 
completely independent pathways to overcome mechanisms of resistance to both classical 
chemotherapeutic agents and molecularly targeted drugs.
Keywords: multidrug resistance, microarray analysis, ovarian cancer, drug extrusion, drug 
inactivation
Introduction
Ovarian cancer represents only 10% of all gynecological cancers in Europe,1 but has 
the highest mortality rate among them. This is mostly due to the resistance of ovarian 
cancer to current chemotherapy regimens. Although most patients initially respond 
to chemotherapy, a significant percentage of them relapse and develop resistance to 
a broad spectrum of structurally unrelated drugs that do not share a common target. 
Consequently, ovarian cancer becomes refractory to the different alternatives for its 
treatment and is typically incurable. Indeed, 90% of the deaths from ovarian cancer 
can be attributed to drug resistance.2
The phenomenon of MDR is multifactorial, and may result from a variety of 
cellular mechanisms, such as activation or overexpression of drug-export proteins 
involving Pgp, as well as other associated proteins;3 alteration of target enzymes, 
such as mutated topoisomerase II;4 increased drug metabolism and elimination, due 
to altered expression of cytochrome P450 enzymes;5 alterations in cell-cycle control 
or changes in apoptotic threshold;6 enhanced intracellular drug inactivation, due to 
conjugation with glutathione;7 and alterations in DNA-repair ability.8 Furthermore, 
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the multicellular structure of cancer displays a set of 
transport barriers to drug delivery. The ECM of tumor cells 
allows the formation of dense cellular structures that limit 
drug diffusion into cells that are localized away from the blood 
vessels.9,10 In addition, the interaction of the ECM with cancer 
cells can affect their sensitivity to apoptosis and DR.11
Drug export is the most prevalent and important mecha-
nism of DR. Therefore, most studies attempting to circumvent 
MDR have been focused on the possibility of modulating 
the activity of Pgp or associated proteins like breast cancer- 
resistance protein by using competitive inhibitors or modu-
lating its expression (for a review, see Wu et al12). MDR 
reversion through inhibition of Pgp was first achieved in vitro 
using verapamil,13 and several years later using other unre-
lated compounds, such as cyclosporines, phenothiazines, 
antimalarials, or antibiotics. However, at their highest tol-
erable concentration, these drugs failed to achieve clinical 
inhibition.12 Although alternative Pgp modulators with higher 
specificity have been produced, clinical trials have evidenced 
that elimination of Pgp+ cells through the combined use of 
chemotherapeutics and Pgp modulators may lead to the 
selection of cells presenting alternative MDR mechanisms.14
In the last few years, it has become clear that the devel-
opment of an MDR-cell population does not arise from a 
single mechanism, but likely from multiple stacked pro-
cesses. Cancer heterogeneity explains the fact that every 
cancer expresses a different array of DR genes, and that even 
cells within the same cancer can exhibit a large amount of 
heterogeneity regarding DR.15 Resistance to new tumor-cell-
specific therapies has also been described. Importantly, the 
mechanisms of resistance to these new drugs are identical 
or at least overlapping to those causing resistance to the 
classical drugs.16
The NCI/ADR-RES human cell line is a model for the 
study of MDR in ovarian cancer. To get a better comprehen-
sion of the enormous amount of published works related to 
this cell line, a study of the MDR mechanisms developed 
in NCI/ADR-RES compared to its parental OVCAR-8 is 
needed. In the present work, we identify changes in gene 
expression of NCI/ADR-RES cells compared to OVCAR-8. 
We used gene-expression profiling to identify those genes 
and pathways that may be important for the development 
of DR in ovarian cancer. Overall, a better understanding 
of how DR arises may ultimately lead to new approaches 
for overcoming resistance and improving patient survival. 
Large-scale expression analysis is an attractive strategy to 
study MDR, because it is a multifactorial phenomenon that 
involves multiple genes and pathways. Therefore, it can 
identify new candidate genes involved in MDR that can be 
targets for cancer therapy.
Materials and methods
cell lines and culture conditions
The MDR NCI/ADR-RES human ovarian cancer cell line 
(formerly MCF7/ADR)17 was a generous gift from Dr Ramon 
Colomer of the Institut Català d’Oncologia de Girona, 
Hospital Universitari de Girona Dr Josep Trueta (Girona, 
Spain). It was initially obtained from the American Type Cul-
ture Collection and used immediately after resuscitation. The 
OVCAR-8 human ovarian cancer cell line was obtained from 
the Division of Cancer Treatment and Diagnosis, National 
Cancer Institute (Rockville, MD, USA) and used immediately 
after resuscitation. NCI/ADR-RES and OVCAR-8 cells were 
routinely grown at 37°C in a humidified atmosphere of 5% 
CO
2
 in Dulbecco’s Modified Eagle Medium and Roswell 
Park Memorial Institute, respectively, supplemented with 
10% FBS, 50 U/mL penicillin, and 50 μg/mL streptomycin 
(Thermo Fisher Scientific, Waltham, MA, USA). In addition, 
NCI/ADR-RES cells were maintained in media containing 
1.84 μM doxorubicin (Tedec-Meiji Farma, Madrid, Spain). 
Cells remained free of Mycoplasma and were propagated 
according to established protocols.
Cell-proliferation assay
NCI/ADR-RES cells (7,000 per well) and OVCAR-8 cells 
(2,500 per well) were seeded into 96-well plates. After 
24 hours of incubation, cells were treated for 72 hours with 
varying concentrations of a particular chemotherapeutic 
among the following: doxorubicin, paclitaxel, docetaxel, 
cisplatin, carboplatin, gemcitabine, and etoposide. Sensi-
tivity was determined by the MTT method, as described 
previously.18 Data were collected by measuring the absor-
bance at 570 nm using a Synergy 4 multiwell plate reader 
(BioTek Instruments, Winooski, VT, USA). IC
50
 values were 
calculated by interpolation from the obtained growth curves. 
Data are expressed as means ± SD of three independent 
experiments conducted in triplicate.
rna isolation
NCI/ADR-RES cells (2×105 per well) and OVCAR-8 cells 
(5×104 per well) were seeded into six-well plates. After 
60 hours of incubation, cells were harvested at 400 g for 
5 minutes at 4°C and washed twice with cold PBS. Total 
RNA was extracted using the mirVana miRNA-isolation kit 
(Thermo Fisher Scientific) according to the manufacturer’s 
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instructions and stored at -80°C. Four independent 
preparations were obtained. RNA integrity and 260:280 nm 
absorbance ratio of each sample were checked using an 
Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, 
CA, USA) and a NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific), respectively.
Gene-expression microarray analysis
Gene-expression microarray experiments were performed 
at Bioarray (Elche, Spain) using a SurePrint G3 human 
gene-expression microarray (Agilent Technologies), a high-
density oligonucleotide microarray that contains 60,000 
probes, corresponding to 27,958 Entrez Gene RNAs and 
7,419 lncRNAs. Sample preparation and microarray process-
ing were done according to two-color microarray-based gene 
expression analysis (version 6.5; Agilent Technologies) as 
described in Vert et al.19 Also, statistical data analyses were 
done as previously described.19 Genes were considered 
differentially expressed when they had a false-discovery 
rate-adjusted P-value #0.05 and a fold change $2 or #-2. 
The microarray data generated during the current study are 
available under the accession number GSE75494 in the Gene 
Expression Omnibus repository (http://www.ncbi.nlm.nih.
gov/geo).20 The Multiple Experimental Viewer program 
(http://mev.tm4.org) was used to generate a heat map of 
gene expression.
gene Ontology analysis and Kegg 
pathway annotation
Differentially expressed genes were functionally character-
ized with a hypergeometric test to find overrepresented Gene 
Ontology terms in the three main broad ontologies (bio-
logical process, molecular function, and cellular component; 
www.geneontology.org) and were also mapped to the KEGG 
(www.kegg.jp), which assigns proteins to pathways, to find 
overrepresented pathways. Analyses were done using the 
software packages GOstats and RamiGO from Bioconductor 
(www.bioconductor.org). In all cases, P#0.05 was consid-
ered statistically significant.
Transcription-factor target analysis
An in silico prediction of which TFs could be regulating 
multiple genes involved in the maintenance of the MDR 
phenotype in NCI/ADR-RES was made using the TFT-
analysis tool implemented in WebGestalt (http://www.
webgestalt.org).21 We analyzed whether the set of genes 
whose expression change in NCI/ADR-RES compared to 
OVCAR-8 was significantly enriched with TFTs. TFTs are 
specific sets of genes that share a common transcription-
factor-binding site. Enrichment was evaluated through a 
hypergeometric test calibrated by the Benjamini–Hochberg 
procedure with a maximum significance level of P,10-6 as 
the threshold value.
Reverse-transcription quantitative PCR
mRNA expression of four upregulated genes (GALC, 
WNT5A, NOTCH3, EPCAM) and two downregulated genes 
(TOP2A, DCK) was examined by RT-qPCR. The same RNA 
samples used for microarray analysis were used for this 
analysis, which was done according to Vert et al.19 Primer 
sequences for the selected genes were: F, GGCAGACAAC 
AGACGGCACT and R, CATCAACCACCACTC 
GTATCCT for GALC; F, GTGATGCCCTGAAGGAGAA 
GT and R, CGGCTGTTGACCTGTACCAA for WNT5A; 
F, GCTAATGCTGGCTTCCTTCTG and R, GTGTCATC 
TGCCTCATCCTCTT for NOTCH3; F, GCTGTTATTGT 
GGTTGTGGTGAT and R, GCCTTCTCATACTTTGCCA 
TTCT for EPCAM; F, TCCCTTCTATGGTGGATGGTT and 
R, TCTCGCTTGTCATTCCGTTT for TOP2A; and F, GAC 
TGGCATGACTGGATGAATAA and R, CATGTCTC 
TGGAGTGGCTTGA for DCK. To select a constitutive 
gene as a reference for normalizing data, the TA of 
three genes (GUSB, TBP, HPRT1) was measured 
for all samples. The used primer sequences were: 
F, GAACGCCCTGCCTATCTGTATT and R, ATGAGG 
AACTGGCTCTTGGTG for GUSB; F, GGCACCACAG 
CTCTTCCACT and R, TGCGGTACAATCCCAGAACTC 
for TBP; and F, CAGACTTTGCTTTCCTTGGTCA and 
R, AACACTTCGTGGGGTCCTTT for HPRT1. Among 
these, TBP showed the highest stability (lower SD of the 
C
t
) (Figure S1), and thus it was selected as the reference 
gene for data normalization. The RTA of the target genes 
(GALC, WNT5A, NOTCH3, EPCAM, TOP2A, DCK) was 
calculated using:
 
Efficiency
Efficiency
C (control   sample)
target
C (contro
t
t
∆ −
∆ l   sample)
reference22
−
 
where “control” refers to a mix of equal amounts of 
OVCAR-8 samples. Fold changes were calculated as the 
ratio between RTA values obtained for NCI/ADR-RES cells 
and RTA values obtained for OVCAR-8 cells. The absence 
of genomic DNA contamination was checked using non-RT 
controls and the absence of environmental contamination 
using nontemplate controls.
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Results
Cytotoxic effects of different 
chemotherapeutic agents
Figure S2 shows that NCI/ADR-RES was highly resistant to 
different chemotherapeutic agents compared to its parental 
cell line OVCAR-8. As relevant examples, NCI/ADR-RES 
resisted a concentration of doxorubicin more than 500-fold 
higher or a concentration of paclitaxel nearly 230-fold higher 
than OVCAR-8 (Table 1). This cell line was also more 
resistant than OVCAR-8 to different chemotherapeutics 
that are not substrates for Pgp (cisplatin, carboplatin, and 
gemcitabine), although to a minor extent.
Gene-expression changes
We used microarray-derived transcriptional profiling to 
identify differentially expressed genes in the NCI/ADR-RES 
human ovarian cancer cell line relative to OVCAR-8. The 
comparison of gene-expression profiles of NCI/ADR-RES 
and OVCAR-8 cells revealed 927 differentially expressed 
genes of 35,377 present in the microarray (2.62%). Among 
these, 50.2% were upregulated in NCI/ADR-RES cells 
compared to OVCAR-8 (increase ranging from two- to 
135-fold), while 49.8% were downregulated (decrease 
ranging from two- to 130-fold) (Figure 1). Table 2 shows 
the top 20 up- and downregulated genes in NCI/ADR-RES 
cells relative to OVCAR-8. The most upregulated genes code 
for metabolic enzymes (GALC, PTGDS), transmembrane 
transporters and ion channels (ABCB1, CALHM3, SCN2B), 
cell-surface receptors (ITGB4, TACSTD2), secreted pro-
teins (SEMA3D, FGFBP1, CST6), components of the ECM 
(LAMA4, NID2), and transcription regulators (NUPR1). The 
most downregulated genes are mainly receptors (OR7G1, 
OR8B8, OR4D6) and transcription regulators (ZNF699, 
ZNF781, HABP4, UCA1).
Table 1 Cytotoxic effects of different chemotherapeutic agents 
on OVCAR-8 and NCI/ADR-RES cell lines determined by the 
MTT method
Compound OVCAR-8a NCI/ADR-RESa Fold increase
Doxorubicin 0.15±0.04 μM 76.4±5.6 μM 509.3
cisplatin 6.93±1.26 μM 17.8±1.5 μM 2.6
carboplatin 110.6±4.2 μM 177±12 μM 1.6
Paclitaxel 5.94±0.83 nM 1,358±157 nM 228.6
Docetaxel 3.34±0.55 nM 380±15 nM 113.9
gemcitabine 3.97±0.51 nM 44.1±4.2 nM 11.1
etoposide 2.13±0.24 μM 147±10 μM 68.8
Note: aic50 values, corresponding to the concentrations of each antitumor drug 
required to inhibit cell proliferation by 50%, are indicated as mean ± SD.
Abbreviations: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 
ic50, half maximal inhibitory concentration.
Figure 1 Heat map of the differentially expressed genes in NCI/ADR-RES cells 
relative to OVCAR-8.
Notes: Data presented in matrix format, with rows representing individual genes 
and columns representing each sample of NCI/ADR-RES and OVCAR-8 cells. Each cell 
in the matrix represents the expression level (z-score) of a gene in an individual sample. 
Names of the top 20 up- and downregulated genes are indicated. Red and green reflect 
high- and low-expression levels, respectively, as indicated in the scale bar.
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Table 2 Differentially expressed genes in NCI/ADR-RES cells relative to OVCAR-8: top 20 up- and downregulated genes
Probe ID Gene 
symbol
Gene name Fold 
change
Main functions
a_23_P25964 GALC galactosylceramidase 135.2 sphingolipid metabolism
a_32_P29118 SEMA3D sema domain, immunoglobulin domain, short basic 
domain, secreted, semaphorin, 3-D
130.2 Developmental process
Cell differentiation
a_23_P82523 ABCB1 ATP-binding cassette, subfamily B member 1 122.7 Transmembrane drug transport
Cell proliferation
cell cycle
a_33_P3241204 CALHM3 Calcium-homeostasis modulator 3 95.8 ion transport
a_33_P3377364 ITGB4 integrin β4 29.9 Developmental process
cell adhesion
cell motility
signal transduction
a_23_P30126 FGFBP1 Fibroblast growth factor-binding protein 1 26.4 Cell proliferation
cell–cell signaling
signal transduction
a_33_P3391603 LAMA4 laminin α4 20.8 Developmental process
Cell differentiation
cell adhesion
cell migration
a_24_P190472 SLPI Secretory leukocyte-peptidase inhibitor 19.3 immunoresponse
a_23_P163087 NID2 Nidogen 2 (osteonidogen) 18.4 cell adhesion
a_23_P155514 AHSG α2-HS-glycoprotein 16.1 Developmental process
signal transduction
a_23_P406385 FBXL16 F-box and leucine-rich repeat protein 16 15.5 Ubiquitin pathway
a_33_P3298159 PTGDS Prostaglandin D2 synthase, 21 kDa (brain) 13.2 Prostaglandin metabolism
a_23_P146946 CST6 Cystatin E/M 11.9 Developmental process
a_23_P149529 TACSTD2 Tumor-associated calcium-signal transducer 2 11.7 Developmental process
Cell differentiation
Cell proliferation
cell adhesion
cell migration
signal transduction
a_33_P3212109 DCDC2 Doublecortin-domain containing 2 11.1 Developmental process
Cell differentiation
cell migration
signal transduction
a_23_P56746 FAP Fibroblast-activation protein α 9.8 cell migration
cell cycle
a_32_P187571 SCN2B Sodium channel, voltage-gated, type IIβ 8.9 Developmental process
ion transport
a_24_P270728 NUPR1 nuclear protein, transcriptional regulator 1 8 Developmental process
Cell differentiation
Cell proliferation
Regulation of transcription
apoptosis
signal transduction
a_24_P247902 PCLO Piccolo (presynaptic cytomatrix protein) 7.8 synapsis
signal transduction
a_23_P34700 TNNT2 Troponin T type 2 (cardiac) 7.7 Developmental process
Cell differentiation
Muscle contraction
a_32_P200238 UCA1 Urothelial cancer-associated 1 (non-protein-coding) -5.4 Regulation of transcription
a_33_P3592015 HABP4 Hyaluronan-binding protein 4 -5.5 Regulation of transcription
a_33_P3290040 CPT1C Carnitine palmitoyltransferase 1C -5.8 lipid metabolism
a_23_P214821 EDN1 endothelin 1 -5.9 Developmental process
Cell differentiation
Cell proliferation
cell migration
Regulation of vasoconstriction
(Continued)
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RT-qPCR analysis of gene expression
mRNA expression of four upregulated (GALC, WNT5A, 
NOTCH3, EPCAM) and two downregulated (TOP2A, 
DCK) genes in NCI/ADR-RES cells, representative of the 
foremost affected processes, was analyzed by RT-qPCR. 
Fold changes obtained by RT-qPCR, calculated as the ratio 
between RTA values for NCI/ADR-RES cells and RTA 
values for OVCAR-8 cells, were similar to those found in 
the microarray analysis (Figure 2). These results confirmed 
that the microarray experiments were fully valid.
gene Ontology analysis and Kegg 
pathway annotation
To understand the functional relevance of the differentially 
expressed genes better, we performed a Gene Ontology 
analysis. Differentially expressed genes were used to find 
overrepresented Gene Ontology terms in the three broad 
ontology categories: “molecular function”, which captures 
knowledge on the functional activity of gene products; 
“biological process”, as part of which these specific func-
tions collectively act; and “cellular component”, where all 
this occurs. To the same end, differentially expressed genes 
were mapped to the KEGG database to find overrepresented 
metabolic and regulatory pathways.
Gene Ontology analysis showed that up- and down-
regulated genes in NCI/ADR-RES cells were related to 
different cellular events (Table 3). Regarding biological 
process ontology, the terms with the highest number of 
Table 2 (Continued)
Probe ID Gene 
symbol
Gene name Fold 
change
Main functions
a_23_P326760 MYRIP Myosin Viia and rab interacting protein -5.9 Regulation of exocytosis
Secretory granule organization
a_23_P419786 ZNF781 Zinc-finger protein 781 -6.4 Regulation of transcription
a_32_P85999 CDH13 Cadherin 13, H-cadherin (heart) -8.4 Developmental process
Cell proliferation
cell adhesion
cell migration
angiogenesis
a_32_P105549 ANXA8L2 Annexin A8-like 2 -9.3 coagulation
a_24_P570583 ZNF542 Zinc-finger protein 542 -9.4 Pseudogene
a_33_P3420635 OR4D6 Olfactory receptor, family 4, subfamily D, member 6 -10.2 signal transduction
a_23_P62188 ZC4H2 Zinc finger, C4H2 domain-containing -11.5 Developmental process
a_32_P220463 FBLL1 Fibrillarin-like 1 -13.6 rna methylation
Protein methylation
a_23_P1819 OR8B8 Olfactory receptor, family 8, subfamily B, member 8 -14.6 signal transduction
a_33_P3387646 LOC643201 Centrosomal protein 192 kDa pseudogene -15.8 Pseudogene
a_23_P86653 SRGN serglycin -18 Developmental process
Secretory granule organization
apoptosis
a_23_P88249 RBM23 RNA-binding motif protein 23 -24.7 mrna processing
a_23_P433218 OR7E91P Olfactory receptor, family 7, subfamily E, 
member 91 pseudogene
-39.2 Pseudogene
a_33_P3350778 ZNF699 Zinc-finger protein 699 -46.7 Regulation of transcription
a_32_P352358 LOC650293 Seven-transmembrane helix receptor -64.5 Pseudogene
a_33_P3300600 OR7G1 Olfactory receptor, family 7, subfamily G, member 1 -129.9 signal transduction
Note: Gene information was taken from the UniProt database (European Bioinformatics, UK; Swiss Institute of Bioinformatics, Switzerland; Protein Information Resource, 
Usa; http://www.uniprot.org) and from the Entrez Gene database (National Center for Biotechnology Information, USA; http://www.ncbi.nlm.nih.gov/gene).
Figure 2 Quantitative comparison of gene-expression changes in NCI/ADR-RES 
relative to OVCAR-8 cell line.
Note: Comparison of fold-change values of the indicated genes (NCI/ADR-RES 
relative to OVCAR-8 cells) obtained by RT-qPCR (gray) and gene-expression 
microarray experiments (white).
Abbreviation: RT-qPCR, reverse-transcription quantitative polymerase chain 
reaction.
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upstream sequences of the differentially expressed genes. 
Table S1 depicts the ten most significant sets of genes 
regulated by a common TF (TFTs). The TFs involved in 
the regulation of the most significant TFTs were TCF3 and 
LEF1. Each of these TFs potentially regulates more than 
140 genes by binding to the target sequences CAGGTG 
and CTTTGT, respectively. Interestingly, among the genes 
potentially regulated by TCF3 and LEF1, four and three, 
respectively, are found in the top 20 upregulated genes in 
NCI/ADR-RES.
Discussion
Gene Ontology analysis and KEGG pathway annotation of 
the 927 differentially expressed genes show interesting terms 
that may allow identifying the different strategies displayed 
by NCI/ADR-RES to maintain its MDR phenotype. Among 
the terms included in Table 3, “cell proliferation” has a low 
P-value, but other terms like “small-molecule metabolic 
genes were “developmental process”, “signal transduction”, 
“cell differentiation”, “small-molecule metabolic process”, 
“response to chemical stimulus”, and “cell proliferation”, 
whereas cellular component ontology favored “extracel-
lular region”, “plasma membrane part”, and “cell surface”. 
In molecular function ontology, we can highlight the term 
“drug binding” for its relation to MDR. Analysis of the 
overrepresented pathways collected in the KEGG database 
showed several affected pathways (Table 3). Among these, 
“pathways in cancer” comprised the highest number of genes. 
We can also highlight the term “extracellular matrix–receptor 
interaction” for its involvement in MDR.
Identification of TFTs among genes with 
expression change in NCI/ADR-RES 
compared to OVCAR-8
Using the TF target-analysis tool of WebGestalt, we searched 
for the presence of potential target sites for TFs on the 
Table 3 Gene Ontology analysis and KEGG pathway annotation of up- and downregulated genes in NCI/ADR-RES
Analysis Term Gene counta % upregulated % downregulated P-value
gene Ontology: 
biological process
Cell proliferation 123 52.8 47.2 6.46-7
Extracellular matrix organization 24 62.5 37.5 1.98-4
angiogenesis 35 45.7 54.3 2.60-4
Developmental process 272 52.6 47.4 7.26-4
growth 59 55.9 44.1 1.65-3
response to chemical stimulus 175 53.1 46.9 1.98-3
response to oxygen levels 23 56.5 43.5 3.13-3
Small-molecule metabolic process 159 56.0 44.0 5.29-3
signal transduction 245 54.3 45.7 6.12-3
cell adhesion 64 60.9 39.1 2.10-2
cell migration 57 57.9 42.1 2.49-2
Cell differentiation 158 50.6 49.4 4.86-2
gene Ontology: 
molecular function
Peptidase-regulator activity 22 77.3 22.7 7.47-4
Growth-factor binding 14 78.6 21.4 8.00-4
collagen binding 8 75.0 25.0 1.93-3
glycosaminoglycan binding 17 76.5 23.5 6.27-3
lipid binding 48 52.1 47.9 3.73-2
Kinase-regulator activity 12 58.3 41.7 3.86-2
Drug binding 8 37.5 62.5 4.85-2
gene Ontology: 
cellular component
extracellular region 152 65.8 34.2 4.04-6
lysosome 33 63.6 36.4 2.08-4
Cell surface 37 70.3 29.7 6.99-3
cell–cell junction 24 70.8 29.2 1.09-2
Plasma-membrane part 114 72.8 27.2 1.85-2
golgi lumen 8 62.5 37.5 3.67-2
Kegg pathway 
annotation
complement and coagulation cascades 9 66.7 33.3 7.18-3
PPAR-signaling pathway 9 55.6 44.4 7.89-3
extracellular matrix–receptor interaction 10 70.0 30.0 9.71-3
cell cycle 12 25.0 75.0 2.13-2
nitrogen metabolism 4 75.0 25.0 2.60-2
Pathways in cancer 24 54.2 45.8 3.69-2
Ubiquitin-mediated proteolysis 12 33.3 66.7 3.81-2
Note: aNumber of differentially expressed genes that belong to these terms.
Abbreviation: KEGG, Kyoto Encyclopedia of Genes and Genomes.
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process”, “signal transduction”, “response to chemical 
stimulus”, “drug binding”, or “ECM organization” help to 
identify those processes that allow this cell line to be highly 
resistant to different anticancer drugs.
Changes in expression of genes involved 
in drug extrusion
The Gene Ontology “cell proliferation” and “small-molecule 
metabolic process” terms include the ABCB1 gene coding 
for Pgp. Overexpression of this gene is the most known 
mechanism of MDR in NCI/ADR-RES cells.23 In our study, 
ABCB1 is the third-most upregulated gene in NCI/ADR-
RES compared to OVCAR-8 (increment of approximately 
123-fold, Table 2). The Pgp-efflux pump is responsible for 
decreased drug accumulation in cells of a broad spectrum of 
chemotherapeutic agents, such as doxorubicin, daunorubicin, 
paclitaxel, docetaxel, etoposide, irinotecan, vinblastine, vin-
cristine, and actinomycin D, among many others.24 In addition 
to ABCB1, our study reveals that ABCC6 was upregulated 
in NCI/ADR-RES cells. ABCC6 confers resistance to etopo-
side, teniposide, doxorubicin, daunorubicin, actinomycin D, 
and cisplatin.25
The effect of Pgp may be enhanced by galactosylcerami-
dase, encoded by the most upregulated gene (GALC) in NCI/
ADR-RES cells, which catalyzes the hydrolysis of several 
glycosphingolipids to produce ceramide. Although in some 
cancers, reduced expression of GALC has been linked to 
cell survival,26 it has been proposed that ceramide, together 
with Pgp, contribute to DR. Pgp would be involved in the 
encapsulation of drugs into vesicles whose secretion would be 
stimulated by the presence of ceramide in the exosomes.27
changes in genes involved in enhanced 
intracellular drug inactivation or efficacy
The NCI/ADR-RES cell line is much more resistant than 
OVCAR-8 to a wide panel of chemotherapeutic agents 
(Table 1). Among these drugs, cisplatin and gemcitabine are 
not substrates for Pgp. It is thus not surprising that ABCB1 
is not the sole gene responsible for this resistance. In the 
“small-molecule metabolic process” and “drug binding” 
terms, we found other genes involved in MDR, particularly 
in enhancing intracellular drug inactivation. Among the genes 
involved in drug inactivation, we noted the overexpressed 
genes NNMT, CDA, and the underexpressed gene DCK. 
NNMT catalyzes the N-methylation of nicotinamide and other 
pyridines, and is involved in the biotransformation of many 
drugs and xenobiotics.28 Accordingly, it is overexpressed 
in numerous cancers, where it promotes tumorigenesis as 
well as resistance to chemotherapy and radiotherapy via 
regulating nicotinamide metabolism.29,30 CDA is involved 
in pyrimidine salvaging. It catalyzes the hydrolytic deami-
nation of cytidine and deoxycytidine and inactivates, for 
example, gemcitabine by catalyzing its transformation 
into 2′,2′-difluoro-2′-deoxyuridine.31 DCK phosphorylates 
several deoxyribonucleosides and numerous nucleoside 
analogs widely employed as antiviral and chemotherapeutic 
agents. Of note, it catalyzes the first and rate-limiting step 
of the intracellular phosphorylation of gemcitabine to its 
active triphosphate form. Therefore, DCK downregulation 
is an important mechanism for acquisition of gemcitabine 
resistance.31
Interestingly, in the terms “small-molecule metabolic 
process” and “drug binding”, we can find genes whose 
expression levels influence drug efficacy, eg, DCDC2 and 
TOP2A, which are overexpressed and underexpressed, 
respectively. DCDC2 is overexpressed in prostate cancer, 
where it confers resistance to paclitaxel. This effect is 
due to its ability to bind tubulin through the doublecortin 
domains, interfering with paclitaxel-induced disruption of 
microtubule function.32 TOP2A is a DNA topoisomerase 
involved in such processes as chromosome condensation, 
chromatid separation, and the relief of torsional stress that 
occurs during DNA transcription and replication. It is the 
target of several anticancer agents like doxorubicin and 
etoposide. Treatment with these agents is thus more effec-
tive when TOP2A levels are high while suppressing TOP2A 
results in DR.33–35
MDR in NCI/ADR-RES is accompanied 
by architectural and functional 
reorganization of extracellular space
Interestingly, the ECM environment appeared in several 
terms of the Gene Ontology analysis, as well as in KEGG 
pathway annotation (Table 3). Alteration in the expression of 
genes encoding different ECM-related proteins has been asso-
ciated with DR in other ovarian cancer cell lines.36–38 ECM 
may increase DR of a solid tumor by blocking the penetration 
of therapeutic drugs. Our results show that MDR in NCI/
ADR-RES was accompanied by an architectural reorganiza-
tion of the ECM. Therefore, in addition to the intracellular 
mechanisms responsible for MDR, NCI/ADR-RES seems 
to strengthen extracellular barriers against drug delivery. 
The remodeling of the cell microenvironment is revealed 
by changes in the expression of different collagen species 
and other ECM structural proteins. Compared to OVCAR-8, 
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the MDR cell line presents higher expression of the LAMA4, 
NID2, and COL4A4 genes and lower expression of the 
COL4A2, COL4A1, and COL13A1 genes, among others. 
Upregulation of different collagen genes has been described 
in different resistant ovarian cancer cell lines, depending on 
the drug used to induce the resistance,36 although correla-
tions between the kind of drugs that induce the MDR and the 
precise collagen gene over- or underexpressed in each case 
have not been found. Our results reinforce the hypothesis 
that collagen plays an important role in resistance to cancer 
drugs. Interestingly, LAMA4 and NID2 were among the 
20 most upregulated genes in NCI/ADR-RES and were over-
expressed in some ovarian cell lines during the acquisition 
of DR.37,38 The architecture of NCI/ADR-RES ECM may 
also be modified, because we detected the overexpression 
of several collagen-modifying enzymes like MMP1 and 
LOXL4, among others. These proteins have previously been 
related to the establishment of an MDR phenotype.39,40
The MDR phenotype can also result from the inter-
action of ECM proteins with cellular receptors, leading 
to resistance to drug-induced apoptosis, a phenomenon 
known as cell adhesion-mediated DR. Several studies have 
demonstrated that integrin–ECM signaling promotes cell 
adhesion-mediated DR and provides a survival advantage 
against numerous chemotherapeutic drugs.41 Integrins 
modulate many signaling pathways, including the PI3K–Akt, 
ERK, and NFκB pathways, thus implying that they may also 
be important factors in resistance to kinase-targeted agents. 
Interestingly, ITGB4 and ITGB8 are highly overexpressed 
in NCI/ADR-RES cells. ITGB4 confers resistance to vari-
ous cytotoxic drugs, such as doxorubicin, tamoxifen, and 
etoposide, by activating the PI3K–Akt and the prosurvival 
NFκB pathways in different kinds of cancer,42–44 whereas 
ITGB8 enhances resistance to gefitinib, probably through 
interaction with the TGFβ pathway.45
Another interesting gene of the ECM that deserves con-
sideration is TGFBI, which is one of the most downregulated 
genes in NCI/ADR-RES cells. TGFBI is a secreted protein 
that binds to many extracellular proteins and becomes part 
of the ECM, where it regulates cell adhesion. It has been 
described that the loss of this protein is sufficient to induce 
resistance to paclitaxel, etoposide, cisplatin, and gemcitabine 
in different cancers.46
Three of the most overexpressed genes in NCI/ADR-RES 
compared to OVCAR-8 code for proteins that are located 
in the extracellular space: SEMA3D, FGFBP1, and SLPI. 
These genes have been found overexpressed in different 
cancers, including ovarian cancer, where they play crucial 
roles ranging from tumor growth and angiogenic stimulation 
to invasiveness and metastasis.47–49 It is interesting to note 
that overexpression of SEMA3D compared to its parental cell 
line has also been observed in MDR resistant K562 leukemia 
cells47 and also that SLPI induces paclitaxel resistance.48 The 
overexpression of SEMA3D, together with that of ITGB4, 
has been recently confirmed on a global proteomic analysis 
of OVCAR-8 and NCI/ADR-RES cells.50
Finally, we found upregulation of EpCAM, a transmem-
brane glycoprotein with roles in cell–cell adhesion, migra-
tion, and proliferation.51 EpCAM is overexpressed in most 
human cancers including ovarian cancer.51,52 High expression 
of EpCAM is associated with increased resistance to different 
drugs, such as docetaxel, paclitaxel, doxorubicin, cisplatin, 
and 5-fluorouracil.53–55
NCI/ADR-RES overexpresses genes 
involved in pathways that trigger MDR
Our results show that NCI/ADR-RES cells display multiple 
mechanisms for DR, which would be difficult to tackle with a 
single antitumor strategy. Ontological and TFT analysis helps 
to understand how these multiple mechanisms are maintained 
in the cell. The KEGG analysis included nine genes in the 
term “PPAR-signaling pathway”. Among them, most of 
the genes that are overexpressed are repressed by some of 
the PPARs. Conversely, most of the genes that are under-
expressed are activated by some of the PPARs (Table S2). 
Furthermore, the genes of the most significant set of TFTs 
are regulated by TCF3 (Table S1), which represses the PPAR 
signaling.56 Altogether, these observations may indicate that 
the PPAR-signaling pathway is less active in NCI/ADR-
RES than in OVCAR-8. Of note, it has been described that 
the PPAR pathway could be a negative regulator of ABCB1 
transcription57–59 which is in accordance with our results.
Among the genes grouped in the Gene Ontology terms 
“signal transduction” and “response to chemical stimulus”, 
we identified genes involved in the MAPK–Akt-, Wnt-, and 
Notch-signaling pathways. These pathways have previously 
been found to be related to DR.60–62 We detected different 
transducers involved in the activation of MAPK and PI3K–
Akt signaling that are overexpressed in NCI/ADR-RES 
compared to OVCAR-8. Among them, we noted IGF2, 
TACSTD2, and NUPR1. IGF2 is overexpressed in ovarian 
cancer cells resistant to paclitaxel and other microtubule-
stabilizing drugs, and its inhibition restores paclitaxel sensi-
tivity both in vitro and in vivo.63 TACSTD2 is overexpressed 
in many cancers, including ovarian cancer, and its expression 
in cancer cells has been correlated with DR.64 NUPR1 is also 
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overexpressed in several cancers.65 It confers resistance to 
multiple drugs, including gemcitabine, paclitaxel, and doxo-
rubicin, by inhibiting stress-induced apoptosis and activating 
the PI3K–Akt signaling pathway.66,67
The Wnt–β-catenin pathway seems to be potenti-
ated in NCI/ADR-RES by the overexpression of WNT5A 
and LGR4. WNT5A initiates β-catenin-independent 
Wnt signaling68 and can affect β-catenin–TCF signaling 
depending on receptor context.69 The overexpression of 
WNT5A in NCI/ADR-RES respective to OVCAR-8 cells 
has been previously reported.70 LGR4 potentiates both 
the β-catenin-dependent and independent Wnt-signaling 
pathways.71 The Wnt–β-catenin pathway has been involved 
in ABCB1 regulation in different cancers.72,73 Specifi-
cally, it has been shown that WNT5A upregulates ABCB1 
expression in different MDR cancer cells, including NCI/
ADR-RES,70 and plays a key role in inducing resistance to 
different chemotherapeutic drugs like paclitaxel, oxaliplatin, 
5-fluorouracil, gemcitabine, epirubicin, doxorubicin, and 
etoposide.70,74 LGR4 is overexpressed in cancer cells, where 
it increases invasion, proliferation, survival, and resistance 
to 5-fluorouracil.75–77
The Notch pathway is also involved in DR.60 It seems 
activated in NCI/ADR-RES, since NOTCH3 and DLL1 are 
overexpressed. NOTCH3 is overexpressed in ovarian cancer, 
and its expression correlates with chemoresistance.78 Knock-
down of NOTCH3 inhibits cell proliferation and migration, 
induces apoptosis, and enhances sensitivity to carboplatin, 
cisplatin, and paclitaxel.79,80 DLL1 is a transmembrane ligand 
of the Notch-signaling pathway. It is overexpressed in several 
cancers and linked to enhanced cell proliferation, survival, 
and metastasis.81,82 Moreover, DLL1 has been found to be 
expressed at high levels in patient-derived ovarian cancer 
xenografts with low sensitivity to cisplatin.83
It is widely recognized that multiple TFs are overactive 
in human cancer cells, which make them suitable targets 
for the study of cancer mechanisms. In addition, it is known 
that some of them are abnormally turned on in human 
cancer cells and that this activation occurs through multiple 
mechanisms besides increasing their expression. In the 
present study, common binding sites for TFs shared by sets 
of differentially expressed genes of NCI/ADR-RES have 
been identified (Table S1). Interestingly, four of the six more 
significant sets are regulated by TFs that are activated upon 
β-catenin-dependent or independent Wnt signaling (TCF3, 
LEF1, FOXO4, and NFAT) confirming the importance of 
this pathway in the maintenance of MDR.
TCF3 and LEF1 are members of the TCF/LEF family 
of TFs, which are involved in the Wnt-signaling pathway. 
In the canonical pathway, β-catenin activates transcription 
of target genes through association with the LEF1/TCF TF 
family. In the uncanonical Wnt–Ca2+ pathway, Wnt ligands 
interact with Fzd receptors, producing an increase in intracel-
lular calcium level that subsequently activates the TF NFAT. 
It has also been shown that β-catenin enhances FOXO4 
transcriptional activity.84 Interestingly, seven of the top 20 
overexpressed genes in NCI/ADR-RES are targets of these 
TFs, including ABCB1.
Conclusion
Our results provide information about genes and pathways 
that contribute to the MDR of NCI/ADR-RES and about 
new targets for cancer treatment. Combined drug therapies 
are widely recognized as a fundamental tool in the treatment 
of cancer. However, attacking the same pathway at multiple 
points is not enough to overcome DR. Our findings highlight 
the importance of using orthogonal therapies that target 
completely independent pathways to overcome mechanisms 
of resistance to both standard chemotherapeutic agents and 
molecularly targeted drugs.
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Supplementary materials
Figure S1 Validation of constitutive genes.
Notes: Box plot of threshold cycle (Ct) values of three constitutive genes: GUSB, TBP, and HPRT1. To select a reference for normalizing RT-qPCR data, the transcription abundance 
of these genes was measured for all cDNA samples. Among them, TBP showed the highest stability (lower SD of Ct), and was chosen to normalize the RT-qPCR results.
Abbreviation: RT-qPCR, reverse-transcription quantitative polymerase chain reaction.
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Figure S2 Effect of different antitumor drugs on NCI/ADR-RES and OVCAR-8 proliferation.
Notes: Effect of cisplatin (), carboplatin (), doxorubicin (), etoposide (∆), paclitaxel (), docetaxel (), and gemcitabine () on OVCAR-8 (A) and NCI/ADR-RES 
(B) cells. The curves in the figure are from one representative experiment. Equivalent results were found in at least three independent experiments.
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Table S1 Potential transcription-factor targets for NCI/ADR-RES drug-resistance genes
TF target (TF) Genes P-value
hsa_caggTg_V$e12_Q6 
(TCF3)
COL4A4, EPCAM, IGF2, ITGB4, LAMA4, HIF1A, ITGB8, FBXL16, SCN2B, ABTB2, ACOT11, ACSL4, AHCYL1, AIG1, 
ANK3, ANKRD1, AP1S1, APP, DAK, ARHGAP26, ARL4C, ARL6IP5, ARMCX2, ASS1, HR, BCL11B, BNC2, BUD31, 
CALB1, CAMK2N2, CAST, CCDC85B, CDH13, CDH3, CDYL2, CHRM1, CHST6, CNTLN, COL13A1, CORO2A, CPZ, 
CRABP2, LUM, CTNNBIP1, DCUN1D4, DLL1, DOCK5, IRF1, GAD1, DUSP4, EDN1, EFEMP1, EIF4A2, ELOVL1, 
ENHO, EPAS1, EPB41L4B, EPHX4, ESRP2, F2RL1, FABP3, FAM110A, FAM117B, FAM174B, FAM181B, FAM81A, 
FBXO16, FBXO2, FGD4, FGF1, FGF5, FKBP11, GPRC5B, HDDC3, HOXA3, IER5L, SIM1, IGFBP6, IP6K2, ITPK1, 
KAZALD1, KCNMA1, NAV2, KIF13B, KLF4, KLHL24, KLK1, KREMEN2, LEPREL1, LGALS3BP, LIMD1, MAGI3, 
MDK, METTL8, NOV, NAT8L, NBEA, NCAM2, NPAS2, NPNT, NRGN, NRIP3, NTRK2, PAQR5, PAX2, PCDH1, 
PCDHA6, PCM1, PDE1C, PDGFB, PFKFB2, PGM5, PLCD3, POLR1D, POLR3G, PRSS12, PTGIR, PTPRK, TLE4, 
RASAL1, RGS3, RGS7, RNF182, ROBO3, RTKN2, S1PR1, SCG5, SCN3B, SKP2, SLC29A2, SLC30A3, SLC9A7, 
SLCO2A1, SMAD3, SMURF2, SNAP25, SPINT2, SPRY4, SSX2IP, STARD13, STRA6, TLX2, SYNPO2L, TACC2, 
TAPBPL, TBC1D8, TECPR1, TGFB3, TGM1, THBS3, TMEM139, TMEM184A, TRAK1, TRIB2, TRIM7, TRPS1, 
TSC22D3, VCAN, TSPAN13, UBE2J1, UBE2L6, UNC13D, WARS2, WBP4, WDR47, WNK2, ZDHHC2, ZNF503
5-39
hsa_cTTTgT_V$leF1_Q2 
(LEF1)
LAMA4, NID2, NOTCH3, ITGB8, FAP, ADAM19, ADAMTS5, AHCYL1, ANK3, ANKRD10, AP4B1, APP, ARHGEF19, 
ARHGEF7, ARL4C, ARMCX2, BCL11B, BIK, BIN3, BNC2, BUD31, CAMK2N2, CAB39L, CCDC18, CCDC80, 
CCNE2, CHRM1, CDH11, CDH3, CMPK1, CNOT7, CNTLN, CREB5, CTNNBIP1, DCUN1D4, DCX, DKK1, 
DNAJB4, DLL1, DOCK7, DPYSL4, DUSP1, DUSP4, EFNB2, ENHO, EXTL2, FAM110A, FAM81A, FARP1, GSN, 
FEM1C, FGD4, FOXD3, FOXP1, FRAS1, GAD1, GBE1, GLIPR2, GPC3, GPC6, GPRC5B, GPRC5C, GRK5, HNRPLL, 
HOOK3, HOXA3, HOXB9, HR, HSD17B8, HSPH1, IER5L, IGFBP6, IP6K2, KCTD4, KATNAL1, KLF12, KLHL24, 
LDOC1, LEPREL4, LPHN2, LRRC20, LYPD6, MAP1B, MAPK11, MARCH3, MDK, MITF, MOAP1, MSI2, NAT8L, 
NFIB, NRAS, NRIP3, PAX2, PCDH1, PDE4D, PRCP, PROSER1, PTBP2, PTPDC1, RAP2A, RASAL1, RBM24, RECK, 
RGS3, ROBO4, RTKN2, SAP30, SBSN, SCD, SKAP2, SLC38A2, SMAD3, SORD, SPATA20, ST6GAL1, STARD13, 
STMN3, SYNPO2L, TACC2, TFCP2, THBS3, TIMM23, TMED5, TMEM136, TMEM139, TMEM2, TRIB2, TRIM29, 
TSC22D3, TSPAN13, VANGL1, VCAN, VGLL3, WBP4, WDR47, WNK2, ZDHHC2, ZIC5, ZNF362
1.56-34
hsa_TTgTTT_V$FOXO4_01 
(FOXO4)
ABCB1, ITGB4, LAMA4, WNT5A, HIF1A, ITGB8, ACSL4, AKR1E2, AMIGO2, ANK3, APP, ANKRD28, ARHGAP20, 
BCL11B, BEX1, BIK, BNC2, BUB3, C1S, CAB39L, CALB1, CCDC80, CDC14B, CDH11, CEP120, CLMP, CNN1, 
CPS1, CREB5, DCUN1D4, DCX, DLL1, DMRTA1, DNAJB4, EGR1, DOCK9, DPYSL4, DUSP1, DUSP4, E2F8, 
EFEMP1, EMP1, ESRP2, FAM107B, FAM178A, FGD4, FNBP1, FN1, FOXD3, FOXP1, GNG5, GPC3, GPR39, 
GPRC5C, GRK5, GTF2B, GUCY1A2, HHEX, HSPG2, HNRPLL, HOXA3, HOXA4, HOXB13, HOXB9, HR, IER5L, 
IFIH1, IGFBP1, IGFBP6, IL7R, IP6K2, KLF12, KLHL24, LPHN2, MAGI3, MAP1B, MARCH3, MITF, MSI2, NFIB, 
NOVA1, NPAS2, NRAS, NRP1, NTRK2, PAX2, PDE4D, PDGFB, PHLPP1, PLXDC2, PPP3CB, PTGER1, PTS, RGS20, 
RGS3, RNF182, ROBO4, S1PR1, SAP30, SH3GLB1, SHOC2, SIM1, SLC16A2, SLC26A2, SLC38A2, SLC7A1, 
SMAD3, ST6GAL1, STARD13, TECPR1, TGFB3, THBS3, TJP2, TNXB, TPPP3, TRPS1, TSC22D3, TSPAN13, 
TWIST2, TXNIP, UBL3, UNC13D, VGLL3, WBP4, ZIC5, ZNF362, ZNF781
3.76-25
hsa_gggcggr_V$sP1_Q6 
(SP1)
IGF2, TOP2A, WNT5A, ITGB8, CST6, ACOT11, AR, ACSS1, ADAMTS5, AP1S1, ARHGAP26, CDH3, ARHGEF19, 
ARL6IP5, ATP10A, BCL11B, BHLHE40, CAMK2D, CAMK2N2, CCDC85B, CCR10, CHST11, CLDN1, CLDN11, 
CNN1, CNOT7, COL7A1, CPT1B, CPT2, DAK, DCUN1D4, DUSP1, EDN2, EIF4A2, ELOVL1, ENHO, ESRP2, 
EXTL2, FAM117B, FDX1, FAM129A, FAM178A, FBXL19-AS1, FBXL2, GAD1, FEM1C, FGF5, FKBP11, GLS, 
GNG4, GPC2, GPC3, GPC6, GSC, HABP4, HCFC1R1, HEXIM2, HHEX, HOXA3, HOXA4, HOXB9, HOXC13, 
HR, HSPA5, HSPH1, IER5L, IGF2BP3, IL11, IP6K2, IQCD, IRS2, KCNMA1, KLF4, KLHL24, KREMEN2, LEPR, 
MITF, LEPREL4, LGALS1, LRRFIP2, MAN1B1, MAN2B1, MAP1B, MARCH3, MOSPD3, MSI2, MST1, NRAS, 
MUC1, NAT8L, NFIB, NRGN, OAT, ODF2, PAX2, PCM1, PDGFB, PDS5B, PFKFB2, PHLDA2, PLTP, PHLPP1, 
PHTF1, POLR1D, POLR3G, PON2, PRCP, PPP3CB, PRICKLE1, PRRT3, PRSS12, RBM24, RECK, RGS16, RGS20, 
RHOF, RND2, ROBO3, RPS23, SAP30, SKAP2, SLC16A2, SLC26A2, TLX2, SLC27A3, SLC30A3, SLC7A1, SLC9A7, 
SMAD3, SOCS2, SPATA20, SPATA2L, SSX2IP, STMN3, SUSD3, TBX1, TFCP2, THBS3, THOC6, TLE4, TLN1, 
TM7SF2, TMED5, TPPP3, TRIB2, TRPS1, VCAN, TSC22D3, TSPAN13, VGLL2, WARS2, WBP4, WDFY2, YIPF1, 
ZNF362, ZNF503
6.64-25
hsa_gggaggrr_V$MaZ_
Q6 (MAZ)
DCDC2, IGF2, NOTCH3, WNT5A, FGFBP1, ITGB8, TNNT2, ACOT11, ADAM19, ADAMTS5, BCL11B, AP1S1, 
ARHGEF19, ARL4C, ASS1, BHLHE40, BNC2, CAMK2N2, CCNE2, CDK8, CHRM1, CHST6, CLDN16, CNN1, 
CPT1B, CTDSPL, CTNNBIP1, CYBRD1, DCX, DKK1, DPAGT1, DUSP4, E2F8, EDN2, EGR1, ENHO, EPAS1, 
EPB41L4B, FBXL19-AS1, FGF5, FAM178A, FAM181B, GJB3, GLIPR2, GPC3, GPR56, GPRC5C, GRK5, GSC, GSN, 
HOXA4, HCFC1R1, HEXIM2, HLA-DMA, HNRPLL, HOXB9, HOXC13, HR, HSD17B8, HSPG2, IGF2BP3, IL11, 
IGFBP6, INPP5F, KCNMA1, KCNS1, KLF12, MITF, KREMEN2, LEPREL4, LGALS1, LRRC20, MAGED1, MDK, 
MSI2, N4BP2L2, NAP1L2, NAV2, NCAM2, NPAS2, NRAS, NRP1, NTRK2, ODF2, PARP12, OTOP2, PAX2, PCDH1, 
PDGFB, PDS5B, PLXDC2, PIGO, POLR1D, PRCP, PRSS12, PTPN7, RAP2A, RBP4, RGS3, RGS7, RHOBTB2, ROBO3, 
ROBO4, RPL15, S1PR1, SBSN, SCD, SCN3B, SERPINB2, SLC13A3, SLC16A2, SLC27A3, SLCO2A1, SNAP25, 
SOCS2, SPARC, SPRY4, SYNPO2L, TACC2, TGFB3, TGM1, THBS3, THOC6, TNXB, TRIB2, TSC22D3, TRPS1, 
UBA3, USH1G, VANGL1, VCAN, WBP4, ZNF362, ZNF503
6.64-25
(Continued)
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Table S1 (Continued)
TF target (TF) Genes P-value
hsa_Tggaaa_V$nFaT_
Q4_01 (NFAT)
WNT5A, HIF1A, ITGB8, FAP, SCN2B, ACSS1, ADM, AGPAT9, AIG1, ALPK2, ANKRD28, ANKS6, AREG, 
ARHGAP20, ARL6IP5, BHLHE40, CAB39L, BNC2, C1S, CALB1, CAST, CCDC18, CCDC80, CDK8, CEP120, 
CHDH, CHST11, CLEC11A, CREB5, CNN1, COL16A1, DCUN1D4, DOCK9, FAM107B, EMP1, EXTL2, FAM110A, 
FAM81A, FBXL19-AS1, FGD4, FN1, FOXD3, FOXP1, GAD1, GDA, GPSM2, GLS, GPER, GRB10, GREM1, GRK5, 
HCFC1R1, GSN, HDDC3, HOXA3, HOXA4, HSD3B7, HSPG2, HSPH1, IL11, IL7R, INPP5F, IP6K2, IRS2, KLF12, 
KCNMA1, LGALS1, LOXL1, MAP1B, MITF, NFIB, NPAS2, NRAS, NRGN, PAQR5, PCDHA6, PDE4D, PDGFB, 
PHTF1, PRSS12, PTGER1, PTP4A2, RGS3, RND2, RNF182, RNF6, SERPINB7, SKP2, SLC27A3, SLC38A2, SLC7A1, 
SLC9A7, SMAD3, SMURF2, SNAP25, SOCS2, SOHLH2, STARD13, TACC2, TBC1D8, TGFB3, THBS3, THOC6, 
TJP2, TNXB, TRIB2, TRPS1, TSC22D3, UBL3, VANGL1, VCAN, VGLL3, WBP4, ZIC5, ZNF502
2.39-22
hsa_aacTTT_UnKnOWn 
(unknown)
ITGB4, LAMA4, HIF1A, ACSL4, ADAMTS5, ADM, AMIGO2, ANGEL1, ANK3, APP, ARHGEF7, BNC2, BAI3, 
BCL11B, BHLHE40, BUB3, CAMK2D, CALB1, CCDC80, CDC14B, CDCA2, CDH11, CDH13, DLL1, CHST11, 
COL13A1, CREB5, ECHDC2, EFNB2, IL11, ENHO, EXTL2, F2RL1, FAM81A, FARP1, FBXO2, FOXD3, FRAS1, 
GLG1, GLS, GNG4, GPC3, GPC6, GPR65, GPRC5B, HCFC1R1, HOXA3, HSD17B14, HOXB9, HSD3B7, HSPG2, 
HSPH1, IER5L, ING1, IRF1, KCNMA1, KCTD4, KCTD9, LRRFIP2, KLF12, KLF4, LPHN2, LUM, MAP1B, MARCH3, 
MAPK11, MITF, MMP24, MSI2, NCAM2, NOVA1, NPAS2, NFIB, NRAS, OXCT1, PAX2, PCM1, PLXDC2, PDGFB, 
PDPN, PDE4D, PDS5B, PRICKLE1, PTBP2, PPP2CB, PRRX2, PRSS12, PTPRK, RAP2A, RGS3, RILPL1, RND2, 
RNF144B, RNF182, SAP30, SIM1, SLC1A3, SMAD3, SOCS2, SPARC, SPTBN2, TLE4, STARD13, TGFB3, THOC6, 
TMEM145, TRPS1, UBA3, VANGL1, VCAN, WBP4, ZIC5, ZNF362
1.32-21
hsa_cTgcagY_
UNKNOWN (unknown)
ABCC6, ANK3, ANKRD28, ANPEP, APP, AR, BEX1, ATP6V1B2, BAI3, BHLHE40, CAMK2D, CCDC85B, CCNE2, 
CDH13, COL7A1, DCX, DNAJB4, EIF4A2, EGR1, ENHO, EPB41L4B, FAM129A, FAM81A, FARP1, FGF1, FOXP1, 
GPC3, HCFC1R1, HEXIM2, HOXA3, IER5L, IP6K2, KLF12, LGALS1, MAGED1, MAP1B, MOAP1, MST1, NAP1L2, 
NBEA, NOVA1, NRAS, NRGN, NTRK2, OTOP2, PCDHB11, PDE4D, PCDHB2, PCDHB5, PDGFB, PNMA3, PTGDS, 
PTX3, RHOBTB2, RND2, SERPINE1, SLCO2A1, SORD, SPRY4, STARD13, SYT12, TACC2, TNXB, TPPP3, TRPS1, 
TSC22D3, TSPAN13, USH1G
1.73-21
hsa_cagcTg_V$aP4_Q5 
(REPIN1)
NID2, HIF1A, LOXL4, ITGB8, TNNT2, ANKRD1, ABTB2, ACSL4, ALPK2, ANGEL1, APP, ARL6IP5, ASS1, BAI3, 
BCL11B, BEX2, BNC2, BRD4, CAST, CCDC85B, CCNE2, CDH13, CDH3, COL7A1, CPS1, DCX, DLL1, DOCK9, 
DUSP1, DUSP4, DYSF, EGR1, FAM110A, FAM178A, FGF1, FOXD3, GOLGA7, FOXP1, FRAS1, GRK5, HHEX, 
HOXA3, HSD17B8, HSD3B7, HSPA5, IER5L, IGFBP6, IL11, KCNMA1, IQCD, KLF12, KLK1, LGALS1, LGI4, 
LOXL1, MDK, MAGED1, MAN2B1, MBP, METTL8, MITF, NBEA, MYO7A, NES, NOVA1, PARP12, PAX2, PDGFB, 
PML, POLR1D, PPP3CB, PRICKLE1, PTGDS, PTGIR, RGS7, RHOBTB2, ROBO4, RRAD, SBSN, SCN3B, SERPINE1, 
SMC1B, SPRY4, SSX2IP, SYNPO2L, STARD13, TGFB3, TLE4, TMEM184A, TMEM25, TPPP3, TRIP11, TSC22D3, 
UFM1, VGLL3, WBP4, WNK2, ZNF503
8.04-21
hsa_TganTca_V$aP1_c 
(AP1)
COL16A1, DLL1, ITGB4, MMP1, LOXL4, CST6, FAP, ACSL4, ADM, AGPAT9, AIG1, ANKRD28, ANK3, APP, ASS1, 
BDKRB1, BUB3, CACNA1A, CD244, CHRM1, CLDN16, COL7A1, CREB5, DCX, DYSF, ELOVL1, EMP1, EPHX4, 
F3, FAM81A, FBXO2, FGF1, GJB3, GLT8D2, GPC3, GPNMB, GPR56, HCFC1R1, HSD3B7, HSPG2, IGFBP6, IL11, 
IL7R, ISG20, LGALS1, LPHN2, LRRFIP2, MAGED1, MITF, NPPB, NRAS, NRIP3, PDE4D, PPP2CB, PFKFB2, PHLDA2, 
PLAU, RBP4, RGS3, RNF144B, RNF182, S1PR1, SBSN, SERPINB2, SERPINB7, SLC38A2, SLC9A7, SNAP25, 
SPARC, STARD13, SPINK6, SPTBN2, SYNPO, TGM1, THOC6, TLX2, TNXB, TRIM29, UCN2, ZNF362, ZNF503
3.69-20
Abbreviation: TF, transcription factor.
Table S2 Predicted effect of PPARs on genes included in the term “PPAR-signaling pathway”
Genea Fold changeb Effect of PPARsc References
CPT1B 2.26 activation (α) 1
CPT2 -2.09 activation (α) 2
CYP27A1 -2.26 activation (γ) 3
FABP3 2.31 activation (α) 4
ACSL4 -2.43 activation (δ) 5
MMP1 4.07 repression (δ) 6
PLTP 2.27 activation (βδ) 7
SCD 2.49 repression (δ) 8
CPT1C -5.81 activation (α) 9
Notes: aGenes marked in bold present a change in expression that is contradictory with an activation of PPARs; bFold change of the expression of genes in NCI/ADR-RES 
relative to OVCAR-8; csubtypes of PPAR receptor described to affect expression of corresponding gene are shown in parentheses.
Abbreviation: PPAR, peroxisome proliferator-activated receptor.
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NCI/ADR-RES displays multiple mechanisms of drug resistance
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